MacroGenics, Inc(NASDAQ:MGNX) 
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in com...
Website: http://www.macrogenics.com
Founded: 2000
Full Time Employees: 384
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.10
H 1.12
L 1.04
C 1.06
V 923,724
10EMA 1.06
20EMA 1.06
60EMA 1.06
120EMA 1.06
250EMA 1.06